Formulation Development
Avenue Therapeutics Reaches Final Agreement with the FDA for Phase 3 Safety Study for IV Tramadol
Avenue Therapeutics, Inc. recently announced it has reached final agreement with the US FDA on the Phase 3 safety study protocol and statistical analysis approach,…
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer
BriaCell Therapeutics Corp. recently released transformational images of the recently reported remarkable responder in the Phase 2 study of BriaCell’s Bria-IMT combination regimen…..
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD
Silo Pharma, Inc. recently provided an update on its previously announced dose-ranging study of SPC-15, a targeted prophylactic treatment for post-traumatic stress disorder (PTSD). The…
Elektrofi & Janssen Biotech Enter Worldwide Collaboration & License Agreement to Exclusively Develop Up to Five Programs Utilizing Elektrofi’s Formulation Technology
Elektrofi, Inc. recently announced it has entered a multi-target worldwide research collaboration and license agreement with Janssen Biotech, Inc. (Janssen), a Johnson & Johnson company. This collaboration will initially focus on developing an at home….
OBI Pharma Announces US FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992
OBI Pharma recently announced the US FDA has cleared an investigational new drug (IND) application for OBI-992, to conduct a Phase 1/2 study of its…
Ampersand Biomedicines Acquires AbCheck to Accelerate Platform and Product Development
Acquisition amplifies Ampersand’s in-house capabilities to generate AND-Body Therapeutics – programmed biologics across a broad range of diseases….
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Athira Pharma, Inc. recently announced completion of enrollment in the Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease. Fosgonimeton…
4DMT & Arbor Biotechnologies Establish Partnership to Co-Develop & Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases
Partnership brings together two leaders in next-generation genetic medicines to engineer, co-develop and co-commercialize (50:50 profit share) AAV-delivered CRISPR/Cas-based therapeutics for up to six product candidates in CNS….
Sanara MedTech Inc. Announces Exclusive License Agreement for Patented Collagen Peptides
Sanara MedTech Inc. recently announced it has signed an exclusive license agreement with Tufts University to develop and commercialize patented technology covering 18 unique….
Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program
Intensity Therapeutics, Inc. recently announced a business update reflecting progress in its Phase 3 sarcoma clinical program. In the fourth quarter of 2023, the company…
GeoVax Announces Issuance of Malaria Vaccine Patent
GeoVax Labs, Inc. recently announced the US Patent and Trademark Office has issued Patent No. 11,857,611 to GeoVax, pursuant to the company’s patent application No.…
Healis Therapeutics Announces Supply Agreement With CKD Bio to Develop CKDB-501 for Neuropsychiatric Indications
Healis Therapeutics recently announced it has entered into a supply agreement with CKD Bio Corporation (A063160.KS) for CKDB-501, a neuromodulator BoNT/A protein. CKD Bio is…
Biora Therapeutics Progresses Research Collaboration for the BioJet Systemic Oral Delivery Platform
Biora Therapeutics, Inc. recently announced its BioJet Systemic Oral Delivery Platform has met key performance milestones as part of its research collaboration with AstraZeneca. The…
Natco Pharma Limited Completes Transition of DASH Pharmaceuticals Into Natco Pharma USA, Furthering Strategic Presence in the US
Natco Pharma Limited recently announced DASH Pharmaceuticals, a company that markets, sells, and distributes generic pharmaceutical products, has officially transitioned to….
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial for the Treatment of Spinal & Bulbar Muscular Atrophy
Avenue Therapeutics, Inc. recently announced all patients have been enrolled in the Phase 1b/2a clinical trial of AJ201 for the treatment of spinal and bulbar…
Silo Pharma & Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia
Silo Pharma, Inc. recently announced an update on its dosage and time-release ketamine-loaded implant, designated as SP-26, which is being developed as a potential at-home…
Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application
Zevra Therapeutics, Inc. recently announced it resubmitted its New Drug Application (NDA) for arimoclomol, an investigational therapeutic candidate for the treatment of Niemann-Pick disease type…
Sever Pharma Solutions Secures DEA License for Controlled Substances Handling in Putnam, CT
Sever Pharma Solutions recently announced the successful attainment of the Drug Enforcement Administration (DEA) license for its site in Putnam, CT. This license, effective as….
4DMT Receives FDA Regenerative Medicine Advanced Therapy Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD
4D Molecular Therapeutics recently announced the US FDA has granted the RMAT designation for the investigational genetic medicine candidate 4D-150 for intravitreal treatment of wet…
Thermo Fisher Scientific’s PPD Clinical Research Business Selected by BARDA to Support Phase 2 Platform Clinical Trial to Treat ARDS
The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, has been selected by the Biomedical Advanced Research and…
